Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) is now available.
Recordati S.p.A. has provided an update on its share buyback program, which began on 30 April 2025, following a resolution from the Shareholders’ Meeting. The program aims to purchase shares for stock option and performance share plans for the management of the Recordati Group. From 1 to 5 September 2025, the company purchased a total of 40,549 shares at an average price of 53.4694 euros per share. As of 5 September 2025, Recordati held 4,204,802 own shares, representing 2.011% of its share capital. This strategic move is part of Recordati’s efforts to enhance its market positioning and provide incentives to its management team.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange. Originating from a family-run pharmacy in Northern Italy in the 1920s, the company now provides therapeutic options in both general and specialist medicine, as well as rare diseases. It operates in a fully integrated manner, covering clinical development, production, marketing, and licensing of active pharmaceutical ingredients and finished products. Recordati is present in about 150 countries across the EMEA, Americas, and APAC regions, employing over 4,580 people worldwide.
Average Trading Volume: 235,659
Technical Sentiment Signal: Strong Buy
Current Market Cap: €11.17B
Find detailed analytics on REC stock on TipRanks’ Stock Analysis page.